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Since its identiﬁcation as the receptor for antidiabetic
thiazolidinedione drugs, peroxisome proliferator-activated
receptor-γ (PPARγ) has been the focus of pharmaceuti-
cal drug discovery programs directed toward ﬁnding bet-
ter drugs for the treatment of diabetes, as well as the ob-
ject of basic research aimed at understanding its role in
the regulation of metabolism. We now understand a great
deal about the crucial role that PPARγ plays in adipocyte
differentiation and development, and are rapidly gaining
knowledge about the role of the receptor in the regulation
ofmetabolism.However,manycrucialaspectsofthemolec-
ular mechanism by which modulation of PPARγ activity
affects insulin resistance and glucose homeostasis are still
notclearlyunderstood.Heretheauthorsreviewthecurrent
status of PPARγ research, with an emphasis on its role in
the causes and treatment of type 2 diabetes.
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MOLECULAR BIOLOGY OF PEROXISOME
PROLIFERATOR-ACTIVATED
RECEPTOR-γ (PPARγ)
PPARγ, together with the closely related receptors PPARα
and PPARδ, comprise the PPAR subfamily of ligand-activated
transcriptionfactors.Althoughstructurallycloselyrelated,each
Received 13 December 2003; accepted 25 January 2004.
AddresscorrespondencetoToddLeff,PhD,DepartmentofPathol-
ogy, Wayne State University School of Medicine, 540 E. Canﬁeld,
Detroit, MI 48201, USA. E-mail: tleff@med.wayne.edu
of the PPAR subtypes display distinct expression patterns and
biological functions [1]. The endogenous ligands for all three
receptors appear to be derivatives of dietary fatty acids and
arachidonate metabolites [2]. PPARα is expressed predomi-
nantly in liver, heart, muscle, and kidney, where it positively
regulates fatty acid oxidation pathways [3]. This function of
PPARα is consistent with the observation that the ﬁbrate class
of lipid-lowering drugs were found to be activators of PPARα
[4, 5]. The function of PPARδ is much less well understood.
It is expressed in most tissues and has been implicated in lipid
homeostasis,keratinocyteproliferation,andwoundhealing[6–
8]. PPARγ is enriched in adipocytes (although it is present in
many tissues) and can be activated by the thiazolidinedione
(TZD) class of antidiabetic drugs [9]. In addition to the role
of PPARγ in regulating metabolism and adipocyte differentia-
tion, which is the subject of this review, molecular and genetic
studies have also established roles for PPARγ in inﬂammation
and atherosclerosis [10–13].
As a member of the nuclear receptor family of ligand ac-
tivated transcription factors, PPARγ has the classical domain
structure shared by most members of this family, with clearly
deﬁned activation, ligand-binding, and DNA-binding domains
(Figure 1). PPARγ activates transcription by binding to short
DNA sequence element known as a PPRE (PPAR response ele-
ment) that are found in the regulatory regions of PPARγ target
genes (i.e., genes whose transcriptional activity is regulated
by PPARγ). The active form of the receptor that binds to the
PPRE is a heterodimer with another ligand-activated transcrip-
tion factor called the retinoid X receptor, or RXR (Figure 1).
RXR functions as a dimeric binding partner for many nuclear
receptors,includingtheotherPPARs,theretinoicacidreceptor,
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FIGURE 1
Upper panel, The domain structure of PPARγ showing the
approximate locations of the N-terminal activation domain
(AF1), the DNA binding domain (DBD), and the ligand
binding domain (LBD). The shaded area indicates the
28–amino acid N-terminal domain that is present in the
PPARγ2 isoform but not in the PPARγ1 isoform. Lower panel,
Schematic diagram representing a PPARγ/RXR dimer bound a
PPAR-speciﬁc regulatory element (PPRE) located in the
upstream regulatory region of a typical PPARγ-regulated gene.
and the thyroid hormone receptor. Because RXR itself is also
activated by speciﬁc ligands, its presence adds an additional
dimension to transcriptional regulation by PPARγ.
The molecular mechanism by which PPARγ activates tran-
scription in response to thiazolidinediones is similar to how
othermembersofthenuclearreceptorfamilyactivatetranscrip-
tion in response to binding the appropriate ligand (for a more
detailed review of the molecular mechanisms of transcriptional
activation by nuclear receptors see [14]). In the absence of lig-
and, the transcriptionally inactive PPARγ/RXR dimer can still
bind DNA and occupy PPRE recognition sequences in PPAR
targetgenes.Inthisunligandedstate,thePPAR/RXRdimercan
interact with one of several transcriptional accessory proteins
referred to as corepressors. These corepressors proteins (e.g.,
N-Cor or SMRT) have histone-modifying activities that act to
maintainthelocalchromatinconﬁgurationinatranscriptionally
inactive form. The binding of a TZD (or any other agonist) to
PPARγ inducesachangeinthestructureofthereceptorthatre-
ducesitsafﬁnityforthecorepressorandincreasesitsafﬁnityfor
another class of transcriptional accessory proteins called coac-
tivators. Transcriptional coactivators, such as P300 SRC1 or
CBP,carryoutvariousfunctionsthatincreasethetranscriptional
activity of the PPAR target gene. Some coactivators contain
a histone acetylase enzymatic activity that modiﬁes the local
chromatin structure to a more open or active form. In addition,
coactivators may mediate an interaction between the receptor
and the RNA polymerase complex that increases its transcrip-
tional activity. It is the ligand-induced exchange of corepressor
forcoactivatorproteinsthatleadstoanincreaseinthetranscrip-
tional activity of PPARγ target genes after ligand treatment.
The PPARγ protein is found in tissues throughout the body,
butismosthighlyexpressedinadiposetissue.Therearetwoma-
jorformsoftheprotein,PPARγ1andPPARγ2,thatareencoded
by the same gene but transcribed from different promoters. The
PPARγ2 protein is identical to PPARγ1 except for an addi-
tional 28 amino acids at the N-terminus in the human protein
(Figure1).ThefunctionaldifferencebetweenthesetwoPPARγ
isoforms is not clearly understood, although as described be-
low PPARγ2 may have a more dominant role in regulating the
process of adipocyte differentiation. It is not clear which of
the two isoforms plays a more important role in mediating the
therapeutic actions of the TZD drugs.
PPARγ PLAYS A MAJOR ROLE IN ADIPOCYTE
DIFFERENTIATION
PPARγ was initially recognized as a transcription factor
involved in the activation of the adipocyte fatty acid binding
protein aP2 during the differentiation of adipocytes from un-
differentiated precursor cells [15], and it was rapidly recog-
nized as playing a central role in the process of adipogenesis
[16]. It is now known that the presence of PPARγ is absolutely
required for the formation of adipose tissue [17]. As will be
discussed later in this review, PPARγ (primarily the γ1 iso-
form) is also present at lower levels in many other tissues, and
probably has important functions outside adipose tissues. On
the other hand, it seems likely that many of the metabolic ef-
fects of thiazolidinedione treatment are the result of PPARγ
activation in adipocytes. In addition, the process adipogenesis
inﬂuencesthenumberofadipocytesinthebody,whichtogether
with adipocyte size, are important determinants of obesity and
ofmultipleparametersofenergymetabolism.Forthesereasons,
thefunctionofPPARγ inadipocytesisofparticularsigniﬁcance
inunderstandingtherelationshipofPPARγ anddisease.Asde-
scribed below, many of the molecular details of the adipocyte
differentiation process that generates mature adipocytes from
ﬁbroblast-like precursor cells are now known.
ItisimportanttonotethatourunderstandingofhowPPARγ
participates in the generation of mature adipocytes from pre-
cursor cells is based primarily on in vitro models of adipo-
genesis such as the mouse 3T3L1 cell line. Although these
cell lines are very amenable to experimentation, they produce
adipocytes that are strikingly different in some respects than
native adipocytes found in adipose tissue in vivo. For example,
fully differentiated 3T3L1 adipocytes are multilocular (contain
multiple lipid droplets), whereas native adipocytes in white fatPPARγ AND DIABETES 101
(the predominant type of adipose tissue in humans) display a
uniloculardistributionoflipid.Althoughweknowthatmanyof
the characteristics of adipocyte differentiation in cultured cell
lines are also important features of in vivo adipogenesis, it is
important to bear in mind that some aspects of adipogenesis
that have been learned from cell culture systems, as described
below, may differ from the process as it occurs in vivo.
Conﬂuent cultures of 3T3L1 ﬁbroblasts can be induced
to differentiate into adipocytes by treatment with a hormonal
cocktail containing insulin, dexamethasone, and a phosphodi-
esterase inhibitor (for a detailed review of the molecular bi-
ology of adipogenesis see [18]). One of the ﬁrst steps in this
process is the reentry of growth-arrested preadipocytes into the
cell cycle and the completion of several rounds of clonal ex-
pansion. Multiple genes involved in the cell-cycle control are
required for this step to proceed, including the tumor suppres-
sor retinoblastoma protein (Rb) and several cyclin-dependent
kinases and their inhibitors (p18, p21, and p27). This and sub-
sequent steps of the program of adipogenesis are controlled to
a large degree by a cascade of gene expression events regulated
by a small set of transcription factors. Together with PPARγ,
the three CCAAT/enhancer-binding proteins C/EBPα,- β, and
-δ compriseprimarythesetoftranscriptionfactordeterminants
of adipogenesis.
One of the initial steps in the transcriptional cascade initi-
ated in response to adipogenic signals is the rapid induction
of C/EBPβ and -δ expression. These transcription factors or-
chestrate cell-cycle reentry by stimulating the expression of
the CDK inhibitor p21, which acts to inhibit the Rb protein
and relieve its block on cell-cycle progression. C/EBPδ and
-β have also been shown to induce expression of the PPARγ
gene that goes on to play a key role in subsequent steps in
the differentiation process. The importance of C/EBPβ and -δ
for adipogenesis was clearly demonstrated by loss-of-function
and gain-of-function genetic studies in mice. Overexpression
of either C/EBPβ or -δ in preadipocytes enhanced adipogene-
sis [19], whereas embryonic ﬁbroblast cells derived from mice
lacking either C/EBPδ or β had reduced levels of adipogenesis
compared with wild-type [20].
The induction of C/EBPβ and δ is immediately followed by
an increase in PPARγ and C/EBPα expression. Although, as
described above, the γ-1 and γ-2 isoforms are nearly identical,
it appears that the two proteins have distinct activities with
regard to adipocyte differentiation. When the expression of the
PPARγ2 isoform was speciﬁcally reduced by introduction of
anartiﬁcialtranscriptionalrepressor,adipogenesiswasstrongly
inhibited [21]. A parallel experiment using a cell line in which
the expression of the both isoforms was knocked down, the
exogenous delivery of only the PPARγ2 isoform into PPARγ-
deﬁcient cells was able to completely restore the adipogenesis,
whereasoverexpressionofonlyPPARγ1hadlittleeffect.Itmay
be that PPARγ1, which is already expressed in preadipocytes,
behaves as a priming factor (along with C/EBPβ and -δ) for the
induction of PPARγ2, and/or cell-cycle regulation to prime the
preadipocytes for the differentiation.
As the program of differentiation proceeds, the expression
ofC/EBPα increasesfollowingtheincreaseinPPARγ2expres-
sion.LikePPARγ,C/EBPαisrequiredforproperadipogenesis,
astargetedgeneknockoutinmiceresultsinembryoniclethality
andfailuretodevelopnormaladiposetissue[22,23].Therehas
been an intense research effort to understand the relationship
betweenthesetwotranscriptionfactorsandtheroletheyplayin
adipogenesis. Several studies have demonstrated that PPARγ
and C/EBPα coregulate each other’s expression. Mice with re-
duced PPARγ expression due to heterozygous gene knockout
displayed a drastically reduced level of C/EBPα [17], and mice
with disrupted C/EBPα expression showed a reduced level of
PPARγ [22]. Introduction of either PPARγ or C/EBPα into
NIH3T3 cells is sufﬁcient to convert these normally nonadi-
pogenic cells from ﬁbroblasts into adipocytes [16, 24]. Using
cell lines missing either the PPARγ gene or the C/EBPα gene,
it was shown that PPARγ could induce adipogenesis in the ab-
senceofC/EBPα,butthattheconversewasnottrue[25].Taken
together, these ﬁndings support a model in which both of the
transcription factors work coordinately to carry out adipogene-
sis; with PPARγ2 playing the primary role and C/EBPα acting
mostly to induce and maintain PPARγ2 expression.
REDUCTION OF PPARγ ACTIVITY BY
GENETIC MUTATION CAUSES DIABETES
Genetic studies have been extremely useful in evaluating
the role of PPARγ in obesity, lipodystrophy and type 2 dia-
betes. To date, a total of seven inherited mutations have been
identiﬁed in the human PPARγ gene (Figure 2) including one
FIGURE 2
Location of mutation in the human PPARγ2 gene, as described
in the text. The shaded area indicates the 28–amino acid
N-terminal domain that is unique to the PPARγ2 isoform. The
numbering system used to describe each mutation is based on
the amino acid sequence of the PPARγ2 isoform. Thus,
V318M and P495L correspond to the V290L and P467L
mutations described in Barroso et al. [27].102 T. LEFF ET AL.
gain-of-functionmutation(P115Q)thatmaybeassociatedwith
obesity [26], four loss-of-function missense mutations [27–29]
associated with lipodystrophy and insulin resistance, and one
frameshift mutation that is associated with diabetes only as a
compound heterozygote with a mutation in the protein phos-
phatase 1 gene [30]. These six mutations are all relatively rare,
affecting very small numbers of individuals. The seventh mu-
tation is a common polymorphism that changes a Pro to Ala
at codon 12 in the N-terminus of the PPARγ2 isoform [31],
which, in some studies, has been associated with a reduced risk
for type 2 diabetes and increased insulin sensitivity.
The P12A Polymorphism in the PPARγ2 Gene
The common P12A polymorphism in the PPARγ gene is
a missense mutation of a CCA-to-GCA at codon 12 in the
N-terminal domain that is unique to the γ-2 isoform. It ap-
pears in the human population with a frequency ranging from
12% in Caucasians to 1% in Chinese [31]. The Ala allele was
associatedwithareducedriskfortype2diabetesinFinnishand
Japanese populations [32], although subsequent studies failed
to ﬁnd an association [33, 34], or even observed an increase in
body mass index in subjects with the P12A mutation [35–38].
However, a recent meta-analysis of six studies concluded that
the Ala allele was generally associated with a 25% reduced
risk of type 2 diabetes [39]. At the molecular level, the Ala
variant showed decreased binding afﬁnity to PPRE sequences
and reduced transcriptional activity [32]. Taken together, these
ﬁndings raise the possibility that a mild reduction, speciﬁcally
in the activity of the PPARγ2 isoform (with PPARγ1 activ-
ity unchanged), causes a small increase in insulin sensitivity
and confers a protection against the development of type 2
diabetes.
PPARγ Mutations Associated With Familial
Partial Lipodystrophy
The lipodystrophies are a heterogeneous group of adipose
tissue disorders characterized by selective loss of fat from var-
TABLE 1
Molecular phenotypes of PPARγ mutations associated with partial lipodystrophy and diabetes
Transcriptional activity
Ligand
afﬁnity Basal Maximal Dom/Neg
Coactivator
binding
Corepressor
binding
V290M ↓↓↓ ↓ Not changed Yes nd nd
F388L ↓↓ Not changed No ↓ nd
R425C ↓↓ ↓ ↓ nd nd nd
P467L ↓↓↓ ↓ Not changed Yes nd ↑
Note. Arrows indicate approximate relative changes in activity as described in text. Dom/Neg, dominant
negative; nd, not determined.
ious parts of the body [40]. Dunnigan-type familial partial
lipodystrophy(FPLD;MIM151660)isanautosomaldominant
syndrome characterized by total loss of subcutaneous adipose
tissue selectively from extremities (visceral fat is unchanged
or increased), and multiple metabolic disturbances including
insulin resistance, diabetes, and dyslipidemia [40]. In some
lineages mutations in LMNA (MIM 150330) encoding nuclear
lamin A/C cause FPLD [41–43]. However, there are families
with FPLD that do not have mutations in the LMNA gene and
thegeneticetiologyofthesyndromeinthesecasesisunknown.
Considering the role of PPARγ in adipocyte biology and the
development of adipose tissue, a PPARγ mutation would be
a reasonable candidate for the genetic cause of FPLD in these
cases.Asoutlinedbelow,fourseparatemutationsinthePPARγ
gene have now been described that cause FPLD and its associ-
ated metabolic disorders.
P467L and V290M
In 1999 O’Rahilly and colleagues identiﬁed two heterozy-
gous mutations in the ligand-binding domain of PPARγ in
three subjects with severe insulin resistance [27]. Both P467L
and V290M mutations were shown to be partially defective
in ligand binding and to have reduced transcriptional activ-
ity (Table 1). Further, in in vitro cell culture systems, both
mutations were shown to inhibit the action of the wild-type
receptor in a dominant-negative fashion. The P467L mutation
involvesaresiduethatiscriticalforligand-dependenttransacti-
vationandcoactivatorrecruitment.Consistentwithitsimpaired
transcriptional activity, the P467L mutant displays markedly
attenuated release of corepressor and recruitment coactivator.
Interestingly, the dominant-negative activity of both of these
mutations can be alleviated by a class of tyrosine-based ar-
tiﬁcial PPARγ ligands, but not by TZD ligands [44]. Clini-
cally, all three subjects show severe hyperinsulinemia, hyper-
tension, and dyslipidemia. Given the proposed role of PPARγ
in adipogenesis, it is important to note that all subjects have
normal body mass index (BMI). Though the initial publica-
tion did not report lipoatrophy or abnormal fat distribution,PPARγ AND DIABETES 103
a subsequent study on the same subjects revealed a form of
partial lipodystrophy in which subcutaneous fat was lost from
the limbs and gluteal region but preserved in both the subcu-
taneous and visceral abdominal fat depots [45]. Euglycemic-
hyperinsulinemic clamp studies on these individuals indicated
markedlyimpairedinsulin-inducedperipheralglucosedisposal
and suppression of hepatic glucose output. Interestingly, the
3- and 9-year-old children of the P467L proband, who are
also carriers of the P467L mutation, showed a three- to four-
fold increase in fasting plasma insulin, suggesting the pres-
ence of insulin resistance. Rosiglitazone treatment of subjects
with the P467L and V290M mutations for 6 months resulted
in signiﬁcant increases in total body fat with an improve-
ment in plasma levels of the adipose-derived hormones leptin
and Acrp30 [45]. This observation suggests that despite the
dominant-negative effects of these mutations, enough PPARγ
activity can be restored by TZD treatment to have a beneﬁcial
effect.
R425C
WhileexaminingPPARγ asacandidategeneinpatientswith
FPLD, Agarwal and Garg [29] identiﬁed a C-to-T heterozy-
gous mutation at nucleotide 1273 in exon 6, which changes a
highly conserved residue, arginine at position 425, to cysteine
(R425C) in one patient. This missense mutation was absent in
DNA samples from four unaffected family members and 48
unrelated healthy individuals. No germline transmission of this
mutation was demonstrated. The affected individual developed
diabetes and hypertriglyceridemia at age 32 years and had a
lossofsubcutaneousfatfromtheextremitiesandface.Although
functionalaspectsofthismutationhavenotbeencharacterized,
examiningthecrystalstructureofPPARγ asdeterminedearlier
by Nolte et al. [46] suggested that Arg425 may be critical for
proper protein folding.
F388L
Recently, a family was identiﬁed with three generations
of subjects with partial lipodystrophy in whom the LMNA
gene was normal. A mutation in the ligand-binding domain of
PPARγ wasidentiﬁedthatcosegregatedwiththelipodystrophy
phenotype [28]. This novel T-to-A mutation at nucleotide 1164
in exon 5 predicted substitution of phenylalanine at codon 388
by leucine (F388L). The mutation was absent from unaffected
family members and 260 normal unrelated subjects. Affected
individualshadprominentmuscularityofcalvesandlowerarms
due to paucity of subcutaneous fat and accumulation of sub-
cutaneous facial, neck, suprascapular, and abdominal fat. All
subjects carrying the mutation had hyperinsulinemia, hyper-
lipoproteinemia, and hypoalphalipoproteinemia. Functionally,
this mutation impairs basal transcriptional activity and reduces
afﬁnity of the receptor for the ligand rosiglitazone. However, in
contrast to the P467L and V290M mutations described above,
the F388L mutation does not exert dominant-negative activ-
ity when transfected together with the wild-type protein into
cultured ﬁbroblasts.
All four of these mutations in the PPARγ ligand-binding
domain appear to cause some degree of reduction in the activ-
ity of the receptor (Table 1). An important issue regarding the
relationshipbetweenPPARγ functionanddiseaseisthedegree
to which these mutations reduce the total amount of PPARγ
activity in cells of affected individuals. Because all of these pa-
tientsareheterozygotesandcarryonenormalPPARγ gene,itis
importanttoknowifthesemutationsactinadominant-negative
fashion and inhibit the activity of the wild-type PPARγ protein
present in the patient’s cells. The P467L and V290M muta-
tionshavebeenreportedtohavedominant-negativeactivityand
would be expected to reduce total PPARγ activity to less than
50%. On the other hand, the F388L mutation does not appear
to be dominant negative, and cells from patients carrying this
mutationwouldbeexpectedtohave50%ormoreofthenormal
amount of PPARγ activity. In spite of these likely differences
in total PPARγ activity, all of the patients have quite similar
symptoms: partial lipodystrophy, insulin resistance, diabetes,
dyslipidemia, and hypertension. Together, these ﬁndings sug-
gest that even a relatively mild reduction in PPARγ activity is
sufﬁcientinhumanstocausethestrikingmetabolicphenotypes
associated with FPLD.
However, several observations suggest that there may not be
a simple relationship between a reduction in PPARγ activity
and metabolic disease. As described above, the P12A polymor-
phism appears to cause a mild reduction in PPARγ activity, but
has been associated with reduced risk of diabetes [39]. This
could be due to the fact that, unlike the lipodystrophy associ-
ated mutations, the P12A change does not affect the PPARγ1
isoform. Another possibility is that the location of the lipodys-
trophy mutations in ligand binding domain (as opposed to the
N-terminus) has a strong effect on the physiological pheno-
type of the mutation. Differences in the phenotypic effects of
these mutants may also be brought about by interaction with
unidentiﬁed modiﬁer genes in either the periphery or the pan-
creas that inﬂuence speciﬁc aspects of glucose homeostasis.
Another very interesting ﬁnding that adds even more complex-
ity is the protection from diet-induced insulin resistance seen
in mice lacking one copy of the PPARγ gene (heterozygous
PPARγ-knockout mice) [47, 48]. The question of how a partial
reductioninPPARγ activityleadstolipodystrophyanddiabetes
in humans but to protection from diabetes in mice will clearly
require additional research and a better understanding of the
molecular mechanism by which PPARγ regulates metabolism
in both mice and humans.104 T. LEFF ET AL.
PPARγ Mutations With Unclear Phenotypes
The P115Q Gain-of-Function Mutation
Ristow et al. [26] reported the presence of a G-to-T muta-
tion in exon 2 of the human PPARγ gene, which was present
in 3% (4 of 121) of obese individuals and in 0% (0 of 237) of
nonobese German Caucasians. This mutation resulted in a sub-
stitution of proline by glutamine at position 115 and prevented
the phosphorylation of an adjacent serine residue at position
114 by mitogen-activated protein (MAP) kinase. Phosphoryla-
tion of PPARγ at this serine has been shown to negatively reg-
ulate its activity [49, 50], suggesting that the P115Q alteration
would be a gain-of-function mutation. Consistent with this no-
tionistheobservationthataPPARγ proteinbearingtheP115Q
mutation had increased activity in an in vitro adipocyte differ-
entiation assay [26]. Although these results strongly suggest
that the P115Q alteration acts as a gain-of-function mutation,
theconclusionthatthemutationcausesobesityisnotsupported
by other experiments. Results from mice bearing phosphory-
lation defective S114A PPARγ mutations were not obese and
in fact were more insulin sensitive than their wild-type coun-
terparts when subjected to a high-fat diet [51]. In addition, the
P115Qmutationhasfailedtoemergeasassociatedwithobesity
in numerous follow-up studies [52–54]. An additional recent
study [55] identiﬁed the P115Q variant in one proband from 48
subjects with impaired glucose tolerance and insulin resistance
(IR). This subject had a lower whole body glucose uptake char-
acterized by euglycemic-hyperinsulinemic clamp studies and
comparable body weight (BMI 28.5 kg/m2) with that of the IR
group (30.3 ± 0.8 kg/m2). Taken together, these results do not
stronglysupportageneticlinkageorcausalconnectionbetween
the P115Q mutation and obesity and diabetes in humans.
The 186 Frameshift/Premature Stop Mutation
The insulin resistance/diabetes syndromes described above
are simple monogenic syndromes. An interesting diabetes-
associatedPPARγ mutationwithamuchmorecomplexgenetic
proﬁle has recently been described [30]. This frameshift muta-
tion causes a premature stop at amino acid 186 in the DNA-
binding domain that produces a completely nonfunctional
receptor. Affected subjects are double heterozygotes for this
mutationinthePPARγ geneandamutationinthePPP1R3gene
that encodes the muscle-speciﬁc regulatory subunit of protein
phosphatase 1, an enzyme that plays a key role in the regula-
tion of glycogen storage. Individuals that had only the PPARγ
frameshift/premature stop mutation or the PPP1RE mutation
hadnodiscernablemetabolicabnormalities.However,thepres-
ence of the two mutations in the same individual resulted in se-
vere insulin resistance, suggesting that an interaction of genes
may underlie metabolic disorders such as type 2 diabetes in
humans.
ACTIVATION OF PPARγ BY TZD
COMPOUNDS IS ANTIDIABETIC
The initial indication that PPARγ plays a crucial role in the
regulation of glucose homeostasis and energy metabolism was
the discovery that antidiabetic drugs of the TZD chemical class
had their beneﬁcial metabolic effects by direct activation of
PPARγ. In patients with type 2 diabetes, treatment with TZD
compounds results in improved peripheral insulin sensitivity
and reduced plasma glucose concentrations [56]. The TZDs
were ﬁrst identiﬁed in the 1980s, prior to the discovery of the
PPARγ receptor and in the absence of any knowledge of their
mechanism of action. In the early 1990s it was independently
discovered that TZDs could cause the differentiation of 3T3L1
preadipocytes[57]andthatPPARγ wasanimportanttranscrip-
tional mediator of adipocyte differentiation [16, 58]. Shortly
thereafter it was determined that TZDs were direct ligands of
PPARγ [9], suggesting that the effects of these compounds on
adipocyteswasmediatedbyactivationofPPARγ [59].Itisnow
generally accepted that the antidiabetic activities of the TZDs
are also mediated by activation of PPARγ. In strong support
of this notion is the observation that other synthetic ligands for
PPARγ that have been selected exclusively for their ability to
activate the receptor show a very similar antidiabetic proﬁle as
the TZDs (for an example see [60]).
In spite of a great deal of work in this area, the mechanism
by which TZDs increase insulin sensitivity and reduce plasma
glucose concentration is not fully understood. It seems likely
that the primary site of action for these drugs is adipose tissue,
as adipocytes contain a higher concentration of PPARγ than
other cell types. There are several possible mechanistic scenar-
ios whereby TZDs could have global effects on metabolism by
acting directly and uniquely in adipose tissue (discussed be-
low). However, several lines of evidence indicate that at least
some of the antidiabetic activity of TZDs is mediated by direct
effectsonmuscle.Insomestudies,diabeticmicegeneticallyen-
gineered to have no adipose tissue still responded to TZD treat-
ment [61], although this was not observed in all fatless mouse
models [62]. In support of the possibility that TZDs have di-
recteffectsinmusclearetworecentpublicationsdemonstrating
that muscle-speciﬁcP P A R γ-knockout mice (animals without
any expression of PPARγ in skeletal muscle, but with normal
expression in all other tissues) are insulin resistant and at least
partially defective in their response to TZD treatment [63, 64].
Althoughtheseﬁndingsdonotcompletelyagreeontherelative
contribution of muscle PPARγ to the overall action of TZD
drugs, they suggest that there is a signiﬁcant role for skeletal
muscle PPARγ in the antidiabetic action of PPARγ agonists
and that the overall physiological effect of TZD treatment is
due to the combined effect of PPARγ activation in muscle as
well as adipose tissue.PPARγ AND DIABETES 105
How might activation of PPARγ in adipose have beneﬁcial
affects on whole body insulin sensitivity? One potential mech-
anism is based on the known function of PPARγ in regulat-
ing adipocyte differentiation pathways. In this model PPARγ
activation leads to an increase in fat-cell number and an im-
provement in the ability of adipocytes to store lipid. It is now
understood that “ectopic” storage of fat in muscle, liver, and
pancreatic islet cells is associated and may contribute to the
metabolic abnormalities in these tissues associated with dia-
betes [65]. A TZD-induced increase in the lipid storage ca-
pability of adipose tissue would act to reduce the degree of
deleterious lipid accumulation in muscle, liver, and pancreas
and improve metabolic function of these tissues. In support of
this model, the known target genes for PPARγ, whose expres-
sion would presumably be activated upon TZD treatment, are
involvedinlipidtransportandstorageandwouldacttoincrease
the lipid storage capability of adipose tissue. In addition, TZD
treatment has been shown to induce the appearance of clusters
of small multiocular adipocytes and loss of large unilocular
adipocytes in diabetic mice and rats [66–68]. It is possible that
these smaller adipocytes are more efﬁcient at lipid storage then
larger adipocytes. Whether the small adipocytes are derived
fromstemcellmitosis,recruitmentofcommittedpreadipocytes,
or possibly by division of mature cells is not known. The loss
of large fat cells was attributed to cellular apoptosis; however,
the impact of TZD treatment on the fate and turnover of mature
adipocytes has not been investigated directly [67].
Consistent with the observations of adipose tissue remod-
eling is the increased subcutaneous fat mass and reduced vis-
ceral fat mass seen in diabetic patients treated long-term with
TZDs [69, 70]. Visceral fat is known to be more lipolytic in re-
sponsetocatecholaminestimulationthansubcutaneousfat,and
to efﬁciently deliver free fatty acids and other secreted factors
to insulin-sensitive tissues such as liver and muscle, possibly
causing an increase in insulin resistance. Although intrinsic
metabolic differences between subcutaneous and visceral fat
are not completely understood, current evidence suggests that
subjects with increased visceral fat are at considerably higher
risk for diabetes and cardiovascular complications than those
with increased subcutaneous fat. These observations, plus the
demonstration that PPARγ levels are higher in subcutaneous
than in visceral fat [71], raise the possibility that PPARγ ac-
tivation by TZDs is fat depot speciﬁc, and that differential ac-
tivation of PPARγ in subcutaneous fat leads to a beneﬁcial
reproportioning of key metabolically active adipose beds.
Another mechanism whereby activation of PPARγ in
adipocytes could have general effects on metabolism is by al-
tering the production of metabolically active adipocyte-derived
hormones (adipokines). In addition to its function as an en-
ergy storage depot, we now understand that adipose tissue is
also a bona ﬁde endocrine organ, secreting hormones that reg-
ulate fat metabolism in other tissues throughout the body. The
list of biologically active peptides known to be secreted by fat
cells has grown signiﬁcantly in recent years, and although the
physiological function of most of these adipokines is not fully
understood, it is clear that they are important components of
the system that orchestrates the control of glucose and lipid
metabolism throughout the body.
Adiponectin (also called ACRP30 or adipoQ) is an excel-
lent candidate for a fat-derived hormone that could mediate the
antidiabetic effects of PPARγ ligands. Originally identiﬁed as
a secreted fat-speciﬁc protein whose expression was induced
during adipogenesis, adiponectin levels were found to be re-
duced in obesity and increased by weight loss. In addition, the
adiponectin gene maps to a region on chromosome 3 that is
associated with diabetes and metabolic syndrome (reviewed in
[72]). Treatment of rodents with adiponectin was found to in-
crease muscle fatty acid oxidation, reverse insulin resistance,
andimprovehepaticinsulinaction[73,74].Theseobservations
raise the possibility that the physiological role of adiponectin
may be to promote lipid oxidation in nonadipose tissue, which
would reduce the amount of stored lipid. Importantly, it has
recently been demonstrated that levels of adiponectin are in-
creased in patients treated with TZDs and that its expression in
adipocytes is induced by PPARγ agonists [73–75].
Another possible adipokine that may participate in medi-
ating the antidiabetic effects of PPARγ ligands is the protein
resistin (also known as adipocyte secreted factor, ADSF, or
FIZZ3). In contrast to adiponectin, resistin appears to have di-
abetes promoting effects on metabolism and was found to be
overexpressed in rodent models of diet-induced obesity and
to induce insulin resistance and glucose intolerance in normal
mice (reviewed in [76]). These data suggest that resistin acts in
a converse manner to adiponectin, increasing insulin resistance
and promoting the development of diabetes. Reports that TZD
treatment reduce circulating levels of resistin [77] support the
possibility that it mediates some of the antidiabetic effects of
these drugs. However this relationship between resistin, TZD
treatment, and diabetes was not observed in all models of the
disease [78, 79] and additional work will need to be carried
out to fully clarify the role of resistin as another potential link
between obesity and diabetes.
Yet another prodiabetic adipokine that is regulated by
PPARγ is the inﬂammatory cytokine tumor necrosis factor
alpha (TNFα), which is secreted by adipocytes under some
circumstances. TNFα production by adipocytes is elevated in
obese rodents and humans and positively correlates with in-
sulin resistance [80, 81] and in some studies inactivation of
TNFα using antibody treatment improved insulin action [82].
As with resistin, the combination of elevated expression in106 T. LEFF ET AL.
obesityandinsulinresistancepromotingactivityofTNFαraises
the possibility that it contributes to the functional link between
obesity and diabetes. Interestingly a mutual antagonism exists
between TNFα and PPARγ: TNFα inhibits PPARγ expression
in adipocytes whereas PPARγ activation by TZDs can par-
tially overcome the diabetogenic effects of TNFα, potentially
explaining at least some of the insulin-sensitizing activity of
PPARγ ligands.
CONCLUSION
It is clear that the PPARγ transcription factor carries out
a variety of crucial functions in multiple tissues that inﬂuence
manyaspectsofphysiologyandmetabolism.However,perhaps
the primary conclusions that can be drawn from a review of the
current literature on the biology of PPARγ is that after many
years of work by a large number of investigators, we still do
nothaveanythingapproachingacompleteunderstandingofthe
mechanisms by which this important protein carries out these
functions. If there is one general lesson that can be taken from
the body of literature, it is that even relatively mild alterations
of PPARγ activity, in either direction, can have a dramatic in-
ﬂuence on many important aspects of the physiology of the
organism. This fact alone is strong motivation for continuing
to work on PPARγ with the ultimate goals of understanding
its exact role in the etiology of metabolic diseases and devising
better PPARγ-targeted therapeutic agents.
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